Targeting the CD47-SIRPA Axis in Oncology Analytical Tool 2020: 76 Drugs in Active Development in Cancer Across 28 Different Targets
Share this article Share this article ResearchAndMarkets.com's offering. Targeting the CD47-SIRPa axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates. This analytical tool is the must have handbook for any business developer, BI/CI operative or clinical dev...
Source: prnewswire.com